Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01151761 · ClinicalTrials.gov registry record · Phase 2
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01151761: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT01151761 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01151761, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
Primary Outcome
Progression free survival is defined to be the time to progression of disease or death.
Interventions
- DRUG Carboplatin
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG Gemcitabine
- PROCEDURE Stereotactic Body Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Why NCT01151761 stopped before completion
NCT01151761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01151761 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01151761 about?
NCT01151761 is a clinical study titled "Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation". The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
What is the current status of trial NCT01151761?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2011-01. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01151761?
The interventions under investigation include: Carboplatin (DRUG), Capecitabine (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Stereotactic Body Radiotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT01151761?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01151761's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia